drugset / Trial / NCT06622694
CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia
Phase 1
Recruiting
15 enrolled
Institute of Hematology & Blood Diseases Hospital, China
Nanjing Bioheng Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is exploratory research aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD13-02, a universal CD7 CAR T therapy, in subjects with relapsed/refractory severe aplastic anemia (SAA)
Timeline
- Start
- 2025-06-19
- Primary completion
- 2026-10-07
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RD13-02 | Cell therapy | — | Intravenous |